Method for predicting response and prognosis of colorectal cancer treatment: T11-056
Patients without KRAS gene mutations can be selected for whom treatment effects can be expected.
■Introduction of Tohoku University Technology As a guideline for administering anti-EGFR antibodies to colorectal cancer patients, it is recommended to test for KRAS gene mutations in the patient's tumor site and to administer anti-EGFR antibodies only to patients without mutations. However, even in patients without mutations, the rate of obtaining a therapeutic effect is low at 30%. Therefore, the present invention provides a new method for selecting patients who should receive anti-EGFR antibodies.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
